<DOC>
	<DOCNO>NCT00233025</DOCNO>
	<brief_summary>To test hypothesis efficacy safety duloxetine beneficial effect reduction pain severity measure average pain item BPI PGI-I patient fibromyalgia syndrome .</brief_summary>
	<brief_title>Duloxetine Versus Placebo Treatment FMS</brief_title>
	<detailed_description />
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Myofascial Pain Syndromes</mesh_term>
	<mesh_term>Duloxetine Hydrochloride</mesh_term>
	<criteria>meet criterion primary FMS define ACR : widespread ache pain four quadrant body axial skeleton great equal 11 18 tender point digital palpation examination measure average pain item BPI Visits 1 2 pain symptom relate traumatic injury , structural rheumatic disease , regional rheumatic disease interfere interpretation outcome measure regional pain syndrome , multiple surgery fail back syndrome confirm current previous diagnosis rheumatoid arthritis , inflammatory arthritis , infectious arthritis , autoimmune disease ( i.e . systemic lupus erythematosus ) current primary Axis I diagnosis major depressive disorder ( MDD ) , include current diagnosis dysthymia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2007</verification_date>
</DOC>